By Ahmed Aboulenein
WASHINGTON (Reuters) – Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk can be convinced to cut the U.S. prices of its popular Ozempic and Wegovy used for weight loss by publicly shaming the drugmaker over how much it charges compared to prices in other countries.
Novo Nordisk CEO Lars Jorgensen is set to testify in front of the Senate Committee on Health, Education, Labor, and Pensions, which Sanders chairs, in a September hearing focusing on U.S. prices for Ozempic and Wegovy.
“I think we got a real shot, and I was pleased to see President Biden supporting that effort,” Sanders told Reuters in a phone interview.
The strategy worked for Sanders last year when he took on Novo, Eli Lilly, and Sanofi over the high price of insulin. All three companies announced they were cutting prices ahead of a scheduled HELP committee hearing following months of pressure.
“I think the major thing that we can do, and we’ve done this successfully in the past with insulin … is to put a focus on the greed of the pharmaceutical industry in general, and Novo Nordisk in particular, in terms of them ripping off the American people,” Sanders said.
Novo Nordisk did not immediately respond to a request for comment on Sanders’ accusations.
“It is very hard for any company, especially one that is making record breaking profits, to defend itself when they are charging the American people many times more for the same exact drug than they charge people in other countries.” Sanders said.
Sanders wants to see Novo reduce the price of Ozempic in the United States to around $155, the drug’s price in Canada.
A month’s supply of Novo’s diabetes drug Ozempic, which has the same active ingredient as Wegovy and is used off-label for weight loss, carries a U.S. list price of $935.77, while Wegovy lists for $1,349.02 per month, according to the drugmaker’s website, although most consumers pay less.
Unparalleled demand for newer weight-loss drugs from Novo and Lilly has led to a surge in their share prices, transforming them into among the world’s most valuable companies.
Sanders acknowledged that he was currently focused on Novo Nordisk because it makes what is on track to become the most profitable drug in history, but said he will “certainly” get to Eli Lilly, which sells rival drugs Mounjaro and Zepbound, describing their prices as “outrageous.”
Mounjaro and Zepbound list for about $1,100 per month.
Some analysts have forecast the total market for weight loss drugs exceeding $100 billion by the end of the decade.
“Eli Lilly is a big player as well. We know that, so we’re not prejudiced against Novo,” Sanders said.
PBMS ALSO IN CROSSHAIRS
Sanders said he plans to introduce legislation that expands the maximum number of drugs eligible for Medicare price negotiations to 50 from 20 a year and extends the annual $2,000 cap on out-of-pocket costs to Americans outside of Medicare. He added that he hopes to secure bipartisan support for the measures.
President Joe Biden called for both provisions in his State of the Union address earlier this year.
Sanders also plans to look at pharmacy benefit managers – the industry middlemen who pharmaceutical companies blame for the high cost of prescription drugs – but said drugmakers could not use them as an excuse.
“To say that PBMs play a negative role is true, but notwithstanding that … (the drug companies) are still ripping off the American people,” said Sanders.
Novo Nordisk only announced its CEO would testify before the Senate committee following a threat of subpoena by Sanders.
“Novo, in all of their press releases, keep saying they want to work in a constructive way with elected officials. They’re not,” said Sanders.
“They have not come back to us with anything constructive.”
(Reporting by Ahmed Aboulenein; Editing by Bill Berkrot)
Comments